Showing 8871-8880 of 9351 results for "".
- No Scrubs? Most Derm Patients Prefer their Docs in White Coatshttps://practicaldermatology.com/news/no-scrubs-most-derm-patients-prefer-their-docs-in-white-coats/2458545/Think you're dressing for success? Think again especially if you are wearing anything other than a traditional white coat when you see patients. The majority of patients prefer their dermatologists to be dressed in white coats, according to a new article pub
- Derms on Sunscreen: Do As We Say and As We Dohttps://practicaldermatology.com/news/derms-on-sunscreen-do-as-we-say-and-as-we-do/2458558/Dermatologists are all on the same page when it comes to sunscreen safety and effectiveness, according to a new survey from the National Society for Cutaneous Medicine (NSCM). Fully 99 percent dermatologists agree that regular use of sunscreens hel
- New Case Study Highlights Black Henna Tattoo Riskshttps://practicaldermatology.com/news/new-case-study-highlights-black-henna-tattoo-risks/2458573/Black henna tattoos should be avoided, especially during foreign travel, UK doctors warn in BMJ Case Reports. Researchers from the University of Sheffiel
- Global Derm Market Set to Soar Through 2022https://practicaldermatology.com/news/global-derm-market-set-to-soar-through-2022/2458579/The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%,
- Valeant Names Joseph C. Papa as Chairman and CEOhttps://practicaldermatology.com/news/valeant-names-joseph-c-papa-as-chairman-and-ceo/2458593/Valeant Pharmaceuticals International, Inc's Board of Directors has named Joseph C. Papa to become its Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. He will join Valeant from Perrigo Company plc, a leading global health
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red
- Checkpoint Inhibitor Shows Promise in MCChttps://practicaldermatology.com/news/checkpoint-inhibitor-shows-promise-in-mcc/2458603/Advanced Merkel cell carcinoma patients who received KEYTRUDA® (pembrolizumab) showed more durable responses than what is typically seen with standard chemotherapy, according to a study presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans and simul
- New MRF White Paper Provides Road Map for Eradicating Melanomahttps://practicaldermatology.com/news/new-mrf-white-paper-provides-road-map-for-eradicating-melanoma/2458604/More research needs to be done about what range of wavelengths in the ultraviolet band need to be blocked to prevent melanoma, according to a new white paper from Melanoma Research Foundation (MRF). The paper, "The Stat
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- GMC, RCS Raise the Bar for Cosmetic Surgery in the UKhttps://practicaldermatology.com/news/gmc-rcs-raise-the-bar-for-cosmetic-surgery-in-the-uk/2458611/Starting in June 2016, the UK will have new rules and regulations governing the practice of cosmetic surgery and the practices of cosmetic surgeons. The new guidance, issued by the General Medical Council (GMC), aims to reign in cosmetic cowboys in the